Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Morphic Therapeutic
company
About
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies.
- 51 - 100
Details
- Last Funding Type
- Seed
- Last Funding Money Raised
- $3M
- Industries
- Biotechnology,Health Care,Medical,Therapeutics
- Founded date
- Jan 1, 2015
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$134.50M
Morphic Therapeutic has raised a total of
$134.50M
in funding over 2 rounds. Their latest funding was raised on
Sep 25, 2018 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 25, 2018 | Series B | $80M | 1 | — | — | Detail |
| Jun 30, 2016 | Series A | $51.50M | 1 | — | — | Detail |
| Jan 1, 2016 | Seed | $3M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Morphic Therapeutic is funded by 1 investors.
Schrödinger
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Schrödinger
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
